¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢(Juvenile
Rheumatoid Arthritis, JRA)
ªø©°Âå°|¨àµ£¹L±Ó®ð³Ý·Àã¬ì ¶À¿[¶©±Ð±Â
²³¦h¨àµ£ºC©ÊÃö¸`ª¢¤¤³Ì±`¨£ªºÀ³Äݨൣ´ÁÃþ·Àã©ÊÃö¸`ª¢¡A¤S¦W¨àµ£´Á¯S²§©ÊÃö¸`ª¢(Juvenile
Idiopathic Arthritis, JIA)¡AÁöµM¤j²¤¤S¤À¦¨¤TºØ«¬¦¡¡A¦ý¥Dnµo¥Í©ó16·³¥H¤Uªº¨àµ£¡A¼vÅT¨àµ£ªºÃö¸`¡A³y¦¨Ãö¸`µoª¢¡A¤Þ°_Ãö¸`¸~µÈ»P¯kµh¡C¨CÓÃö¸`µoª¢·|«ùÄò6¶g¥H¤W¡A¦ý¨ü¼vÅTªºÃö¸`¼Æ¥Ø¡A·|ÀHÃö¸`ª¢ºØÃþ¤£¦P¦Ó²§¡Cµoª¢ªºÃö¸`¡A¦¤W°_§É¬¡°Ê®É¡A·|¦³¡¨¥d¡¨¦íªº·Pı¡AºÙ¬°¡u±á»ø¡v¡Aµ¥¨ì¤¤¤È®É·|·PıµÎªA¦h¤F¡A³o¬OÃþ·Àã©ÊÃö¸`ª¢ªº¯S¼x¡A¦ý¤£¤@©w·|¥X²{¡C
¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢¤À¦¨¤TºØ¨È«¬
1.
¥þ¨«¬¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢(Systemic
JRA)¡G¦û10~20%¨àµ£´ÁÃö¸`ª¢¡AÁ{§Éªí²{°£Ãö¸`µoª¢¯kµh¥~¡A¥Dn¥H¤ÏÂеo¥Íªº¤£©ú¼ö¡A¦X¨Ö¡uÂD³½¦×¦â¡vªº¯»¬õ¦â¥Ö¯l(salmon
rashes)¡Cµo¿N®É¡A¥Ö¯l¥X²{¡A¿N°h®É¡A¥Ö¯l¤S®ø¥¢¡A¥t¥~¡A¦³¨Ç¤pªB¤Í·|¦ñÀH¦³²O¤Ú¸¢¸~¤j¡A¨xŦ»PµÊŦ¤]·|¸~¤j¡A¬Æ¦Ü¦³¦Ø½¤¿n¤ôµ¥²{¶H¡A¥Ñ©ó¨ã¦³¥þ¨©Êªº¨Åé¯gª¬¡A¦]¦Ó±o¦W¡C
2.
¤ÖÃö¸`«¬¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢(Pauciarticular
JRA)¡G¦Û¨àµ£µo¥ÍÃö¸`ª¢°_ªº6Ӥ뤺¡A©Ò¼vÅTªºÃö¸`¼Æ¥Ø¡AY¤Ö©ó(©Îµ¥©ó)4ÓÃö¸`¡AºÙ¤§¡C¦¹ÃþÃö¸`ª¢¦û50%¥ª¥kªº¨àµ£ºC©ÊÃö¸`ª¢¡A³o¸sÃö¸`ª¢±wªÌ¡A¥Dn¤À¦¨¨âÃþ¡A¤@Ãþ¬OÄÝ©ó8·³¥H¤Wªº¨k¥Í¡A²Õ´§Üì(HLA-B27)¶§©Ê¡A®e©ö¦X¨Öµ¬½¤¯fÅÜ(enthesitis)¡A¦¹ÃþÃö¸`ª¢»P»øª½©Ê¯á¬Wª¢Ãö«Y±K¤Á¡A©¹«á¥i¯à·|¼vÅT¨ì¯á¬WÃö¸`¤Î¸zÂËÃö¸`;¥t¤@¤jÃþ¬°¦~Ä֬ƻ´(¦~ÄÖ¤p©ó4·³)ªº¤k¥Í¡A§Ü®Ö§ÜÅé(ANA)§e¶§©Ê¡A¦¹Ãþ±wªÌÃö¸`ª¢¤£¬ÆÄY«¡A¦ý©ö¿©±w²´·úªº¸²µå½¤ª¢(uveitis,
iridocyclitis)¡A³o¨Ç¤p¯f¤H«Øij¦b¿©¯fªº«e¨â¦~¡A¦Ü¤Ö¨C¤TÓ¤ë¬Ý²´¬ìÂå®v¡A¥J²Ó¥Î¤ì»Ø¿O(slit
lamp)Àˬd¡A¥H§K¼vÅTµø¤O¡C
3. ¦hÃö¸`«¬¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢(Poly
JRA)¡G¦ûÃö¸`ª¢±wªÌ30%¥ª¥k¡A6Ӥ뤺¼vÅTÃö¸`¼Æ¥Ø¶W¹L5Ó¡A»P¦¨¤HÃþ·Àã©ÊÃö¸`ª¢¬Û¦ü¡A¼vÅTªº¨àµ£¡A¦~ÄÖ¸ûªø¡A¤k©Ê¬°¥D¡A¥B¸û®e©ö¦³RA
(rheumatoid factor)¶§©Ê¤ÎAnti-CCP¶§©Ê¡A©ö¯}ÃaÃö¸`¡A»Ý¿n·¥ªvÀø¡C
¬°¦ó·|¿©±w¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢?
¤´¥¼ª¾¡A¦ý»OÆW¤H¿©±wªº¾÷²v(²±¦æ²v3.6/105)»P¤é¥»¤H(²±¦æ²v0.8/105)¬Û¦ü¡A¬Ò¤ñ¥ÕºØ¤H¤Ö«Ü¦h¡C®Ú¾Ú§Ú̪º¬ã¨s¡A²Õ´§Üì§e²{HLA-DRB1*0405©ö¿©±w¤ÖÃö¸`¤Î¦hÃö¸`«¬¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢¡A¤Ï¤§¡AY²Õ´§Üì§e²{HLA-DRB1*1502©ö¿©±w¥þ¨«¬¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢¡A©Ò¥H¿ò¶Ç¬O¤@Ó«n¦]¯À¡C¥t¥~´¿¸g¼ÉÅS¹L¬Y¨Ç·P¬Vì¥i¯à¤]¬OP¯f¦]¯À¤§¤@¡A¦ý¥¿½Tì¦]¤´«Ý¬ã¨s¡C
¦p¦ó¶EÂ_¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢(JRA)?
1.Y¤@ÓÃö¸`«ùÄòµoª¢1~2¶g¥H¤W¡A´NÀ³ÃhºÃ¤F!¤@¯ë·P«_¤Þ°_ªºÃö¸`ª¢©ÎÃö¸`µh¡A¤£·|«ùÄò¶W¹L¤@¬P´Á¡A¥B·|¦Û¤v§ïµ½¡AYÃö¸`ª¢«ùÄò6¶g¥H¤W¡A«h¬°¶EÂ_¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢¤§¥²n±ø¥ó¡C
2.·|¼vÅT¦hÓÃö¸`¡G²Óµß·P¬V¤Þ°_ªºÃö¸`ª¢¥u·|¼vÅT¤@Ó¡A¼vÅT¨âÓÃö¸`¥H¤W«h¬Æ¨u¨£¡A¦ý¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢±`·|¦P®É¼vÅT¦hÓÃö¸`¡C
3. ·|¼vÅT¨ì¤pªºÃö¸`¡G²Óµß·P¬V¤ÞPªºÃö¸`ª¢¡A¤@¯ë¼vÅTªºÃö¸`ª¢¥H¤jÃö¸`¬°¥D¡A¦p½¥¡BÆb¡B¨yÃö¸`¬°¥D¡A¦Ó¥B¥u·|¼vÅT¤@ÓÃö¸`¡A¤£·|¦³²¾°Ê²{¶H(§Y¤@¤U¤l¥ª°¼Ãö¸`¡A¤@¤U¤l¥k°¼Ãö¸`)¡A¦ý¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢¡A±`·|¼vÅT¨â°¼Ãö¸`¥B¦hÓÃö¸`¤@¦Pµoª¢¡C
4.
¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢©ö¦³±á»ø²{¶H(morning
stiffness)¡G¤@¯ë¨ü¶ËªºÃö¸`¡A¹B°Ê«á¯kµh·|¥[¼@¡A©Ò¥H¦±á³ÌµÎªA¡A¤U¤È«h·|«Ü¤£µÎªA¡C¦ý¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢¡A«h¬Û¤Ï¡A¦±á°_¨Ó¡A¯S§O¤£µÎªA¡A¦³ºòºò¥d¦íªº·Pı¡A¬¡°Ê°_¨Ó«Ü¤£¤è«K(¿×¤§±á»ø)¡A¦ý¨ì¤¤¤È¹L«á¡A§ïµ½¬Æ¦h¡C
5.
¥ô¦ó¶EÂ_¬°¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢±wªÌ¡AÀ³¥ý±Æ°£¨ä¥L¯e¯fªº¥i¯à©Ê¡A¥]¬A²Óµß·P¬V¡B¥Õ¦å¯fµ¥¡CÀ³¦A¤T±j½Õ¡A¥ý±Æ°£¨ä¥L¥i¯à¤§¯e±w¡A¦A·í§@¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢¨ÓªvÀø¡A¤ñ¸û§´·í¡C
¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢¦p¦óªvÀø?
1.
»Ýn¹Î¶¤ªvÀø¡G¦¨û¥]¬A¨àµ£·Àã¬ì±M¬ìÂå®v¡BªÀ¤u®v¡B´_°·¬ìÂå®v¡B±M¬ìÅ@²z®v¡A³oӹζ¤À³¥i¥H´£¨Ñ±wªÌ¦U¶µ¿Ô¸ß¡A¨Ã§iª¾¦UºØÃĪ«°Æ§@¥Î¡A¨¾¤îÃö¸`ÅܧΡC
2.
ªvÀøªº¥Dn¥Ø¼Ð¡G±±¨îÃö¸`ªºµoª¢¡A´î»´Ãö¸`µoª¢±a¨Óªºµh·¡»P¤£µÎªA¡A¨¾¤îÃö¸`¦]µoª¢¦ÓÅܧΩΤ£µ¥ªø¡A©Ò¥H°ò¥»¤WÀ³¸Óµ¹¤©§Üµoª¢ÃĪ«(NSAIDS)¡AY¸ûÄY«ªº±wªÌ¡AÀ³µ¹¤©²Ä¤G½uÃĪ«(Disease
Modifying Drugs, DMARDS)¡A¨à¬ì¯f¤H¥Dn¨Ï¥ÎªºÃĪ«¥]¬AMethotrexate
(MTX)¡BSulfasalazine¡BAzathioprineµ¥¡A¥t¥~¹ï©ó¨Ï¥Î¥H¤WÃĪ«¤´±±¨î¤£¨}ªÌ¡A¥i¦Ò¼{µ¹¤©¦X¨ÖÀøªk©Î¥Íª«»s¾¯¡A©Î¿×¼Ð¹vªvÀø¡A³o¨Ç·s¤@¥NªºÃĪ«¡A¥]§tAnti-TNF-£\
agents (§Ü¸~½FÃa¦º¦]¤l¡A¥]¬Aetanercept,
infliximab, adalimumab)¡A¦¹¨ÇÃĪ«®ÄªG¨}¦n¡Aªø´Á¤§°Æ§@¥Î«h¤´»Ý¶i¤@¨BÆ[¹î¡C
3.
Ãþ·Àã©ÊÃö¸`ª¢¯fµ£»Ý©w´Á«ô³X²´¬ì¡A´£¨¾¸²µå½¤ª¢ªºµo¥Í¡G¨Ì¾Ú¤£¦PºØÃþªºÃö¸`ª¢¡A¤Î¨ä¥L¦MÀI¦]¤l(¦~ÄÖ¡B©Ê§O¡BANA)¤§¦³µL¡A½Ð¿í·Ó¨àµ£·Àã¬ìÂå®v¤§«Øij¡A©w´Á¦b²´¬ìªù¶E°lÂÜ¡AY¦³¸²µå½¤ª¢¡A»Ý¾¨³t¥B³W«h°lÂܪvÀø¡A¥H§K¤Þ°_¨Öµo¯g¤Îµø¤O»Ùê¡C
µ²½×¡G¨àµ£´ÁÃþ·Àã©ÊÃö¸`ª¢»P¦¨¤HÃþ·Àã©ÊÃö¸`ª¢¬O§¹¥þ¤£¦Pªº¯e¯f¡A¬O§_¦³Ãþ·Àã©Ê¦]¤l(RA)¤ÎAnti-CCP¤£¬O¥²nªº¶EÂ_¼Ðªº¡AÁ{§Éªí¼x¤~¬O¥Dn¶EÂ_ªº¤èªk¡CYªvÀø¤£¾A·í©ö¾ÉP¥|ªÏ¤£µ¥ªø¡A¨Ã¼vÅT¤p«Ä¤lªº¦¨ªøµo¨|¡A¥un¦³®Ä»P¾A·íªºªvÀø¡A¥i´î¤Ö¯e¯f¤ÎÃĪ«±a¨Óªº¨Öµo¯g¡A°ß¦³®aÄÝ»P¯fµ£§¹¥þªº°t¦X¤~¬O¨M©wªvÀø¬O§_¦¨¥\ªºÃöÁä¡C
¡@ |